Another tyrosine kinase member of the EGFR family, HER2, which is usually overexpressed in specific breast cancer subtypes and in some HCC, among other solid tumors [78,79], has also been targeted with novel LYTACs. The gene discussed is ERBB2; the disease is hepatocellular carcinoma.